Albert Seymour
Chief Executive Officer at Seamless Therapeutics
Net worth: 236 708 $ as of 2024-04-29
Albert Seymour active positions
Companies | Position | Start | End |
---|---|---|---|
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Director/Board Member | - | - |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Chief Executive Officer | 2024-04-22 | - |
President | 2024-04-22 | - | |
Chief Tech/Sci/R&D Officer | - | 2024-04-22 |
Career history of Albert Seymour
Former positions of Albert Seymour
Companies | Position | Start | End |
---|---|---|---|
Q32 BIO INC. | Director/Board Member | 2022-09-05 | 2023-11-16 |
Chief Executive Officer | 2022-09-05 | 2023-11-16 | |
Chief Tech/Sci/R&D Officer | 2016-03-31 | 2022-09-05 | |
President | 2022-04-20 | 2023-11-16 | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 2010-12-31 | 2016-02-29 |
Training of Albert Seymour
University of Delaware | Undergraduate Degree |
The Johns Hopkins University | Graduate Degree |
University of Pittsburgh | Doctorate Degree |
Statistics
International
United States | 7 |
Germany | 2 |
Operational
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Technology Services |
- Stock Market
- Insiders
- Albert Seymour
- Experience